ClinicalTrials.gg
CompletedNCT02609126STEPUPUpdated Sep 1, 2021

Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis

A Phase 1 interventional study of EP-104IAR and Vehicle in Osteoarthritis, Knee, sponsored by Eupraxia Pharmaceuticals Inc.. Completed at 3 sites in Canada. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by Eupraxia Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 40 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.

Enrollment
116th of 160
32 · median 63
Started
2016
with 5 others
Phase 1
2 of 171
none open now
Registered
70th of 171
by date

Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 116th largest by enrollment of the 160 interventional ones that give a count, is one of 6 that started in 2016, is one of 2 in phase 1, and was the 70th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Osteoarthritis, Knee with a site in Canada, or all of them as a file.
02

Study summary

The main purpose of this study is to understand the pharmacokinetics of EP-104IAR and to determine whether it is safe to use in patients with osteoarthritis (OA) of the knee. The study will also provide some preliminary insights into whether the experimental treatment reduces pain in the knee.

Osteoarthritis is the most common joint disease, affecting over 20 million people in the US alone. Currently, pain treatments that are injected directly into the knee often work for only a short time and may also have side effects within the rest of the body. The experimental treatment is a steroid that is in the same family of drugs as the most common current injectable treatments for knee osteoarthritis. For this study, the drug is coated with a polymer intended to prolong the time it stays inside the knee and lessen potential side effects.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • osteoarthritis
  • knee
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • OA of Index Knee
  • Kellgren Lawrence Grade 2 or 3
  • Patient-reported pain (PtPain) of Index Knee ≥4 but ≤9
  • PtPain of non-Index Knee \<6
  • ≦ 40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Intra-articular joint injection in the Index Knee within the past 8 weeks for and 6 months for hyaluronic acid
  • Insulin-dependent diabetes
  • Active infection
  • Pregnant or breast feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    EP-104IAR

    15mg EP-104IAR in 4 mL carrier fluid

    Drug: EP-104IAR

  • Placebo comparator
    Vehicle

    4 mL carrier fluid

    Drug: Vehicle

Interventions

  • DrugEP-104IAR

    Single, ultrasound-guided injection of EP-104IAR into the knee

  • DrugVehicle

    Single, ultrasound-guided injection of vehicle placebo into the knee

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of fluticasone propionate

    Time frame: Up to 42 weeks

  2. Fluticasone propionate concentrations in synovial fluid

    Time frame: Up to 30 weeks

  3. Area under the plasma concentration versus time curve (AUC) of fluticasone propionate

    Time frame: 12 weeks

  4. Incidence of treatment-emergent adverse events

    Time frame: Up to 42 weeks

  5. Change from baseline in clinical laboratory parameters: hematology, chemistry (including cortisol) and urinalysis

    Time frame: Up to 42 weeks

Secondary outcomes

  1. Time to baseline pain in patient-reported Pain Numerical Rating Scale for Index knee

    Time frame: Weekly up to 42 weeks

  2. Change from baseline in patient-reported Pain Numerical Rating Scale for Index knee

    Time frame: Weekly up to 42 weeks

  3. Change from baseline in patient-reported Global Assessment of Arthritis

    Time frame: Up to 42 weeks

  4. Change from baseline in patient-reported Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    Time frame: Up to 42 weeks

  5. Change from baseline in patient-reported Short Form - 36 quality of life scores

    Time frame: Up to 42 weeks

  6. Change from baseline in Physician's Global Assessment of Arthritis

    Time frame: Up to 42 weeks

07

Study locations

3 sites
  • Rebalance MD
    Victoria, British Columbia, Canada
  • Centre for Studies in Family Medicine
    London, Ontario N6A 3K7, Canada
  • Fowler Kennedy Sports Medicine Clinic
    London, Ontario N6A 3K7, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Dec 2017, 20 months.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 20 months is above that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2015
First posted
Nov 20, 2015
StartActual
Apr 2016
Primary completionActual
Dec 28, 2017
CompletionActual
Dec 28, 2017
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02609126
Lead sponsor
Eupraxia Pharmaceuticals Inc.
Collaborators
Syreon Corporation
Responsible party
Sponsor
First posted
Nov 20, 2015
Start date
Apr 2016
Primary completion
Dec 28, 2017
Completion
Dec 28, 2017
Last update
Sep 1, 2021

Study contacts

James Helliwell, MD FRCPC
study director · Eupraxia Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion